EGFR and non-small cell lung carcinoma: Following this, osimertinib was compared with standard first‐ and second‐generation EGFR‐TKIs in patients with advanced‐stage EGFR‐positive NSCLC in the pivotal FLAURA trial, revealing a prolonged median PFS (18.9 vs. 10.2 months).95